InvestorsHub Logo
Followers 8
Posts 279
Boards Moderated 0
Alias Born 04/01/2019

Re: MIMadman post# 47006

Monday, 04/22/2019 10:00:43 PM

Monday, April 22, 2019 10:00:43 PM

Post# of 57556
Very true, their product lines are drastically different.

The end result, however, is revenue. Whatever CBD product they’re selling doesn’t necessarily matter. Instead, the question is: how much money are they making?

CBD Unlimited and Canbiola, although they approach the CBD market very differently, generated about the same revenue in 2018. If I remember correctly, CBD Unlimited brought in about $800,000 and Canbiola brought in just under $700,000.

Going forward, CBD Unlimited is expecting to drive $2 million in retail sales each month in 2019, bringing in $24 million for the year.

Likewise, Canbiola is expecting to have 1,650 SAM units distributed in 2019, bringing in $23 million - not including their retail arm.

So, yes, their product line and their approach to the CBD market is very different, but the companies are driving very similar revenue. In that regard, the comparison is extremely valuable in determining market capitalization.